- Oral presentations demonstrate positive preclinical data highlighting CD388's activity against influenza A and B -SAN DIEGO, May 03, 2023 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to save lives and improve the standard of care for patients facing serious diseases, is delivering two oral presentations highlighting new preclinical data on its novel drug-Fc conjugate (DFC) candidate targeting influenza A and B, CD388, at the 7th International Society for…

- U.S. launch of REZZAYO by Melinta expected in mid-2023 -- Company eligible to receive up to an additional $47 million in milestones from multiple existing partnerships based on successful completion of activities planned over the next year - SAN DIEGO, April 24, 2023 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to save lives and improve the standard of care for patients facing serious diseases, today announced receipt of…

SAN DIEGO, March 31, 2023 -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, is scheduled to participate in the following upcoming investor conferences. Event: Cantor Fitzgerald Future of Oncology Virtual SymposiumFormat: Panel DiscussionDate: Monday, April 3, 2023Time: 11:00am ET Event: 22nd Annual Needham Virtual Healthcare ConferenceFormat: Presentation and…

SAN DIEGO, March 23, 2023 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, today reported financial results for the three months and full year ended December 31, 2022 and provided an update on its corporate activities and product pipeline. "We have completed a transformational 2022 for Cidara and are carrying that momentum into 2023 with the recent U.S.…

- REZZAYO is a novel, once-weekly, next-generation echinocandin indicated for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options - - REZZAYO is the first new FDA-approved echinocandin in over a decade - SAN DIEGO and PARSIPPANY, N.J., March 22, 2023 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) and Melinta Therapeutics, LLC today announced that the U.S. Food and Drug Administration (FDA) approved REZZAYO™ (rezafungin for injection) for the…

SAN DIEGO, March 07, 2023 -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, presented preclinical data on a CD73-targeting drug-Fc conjugate (DFC) candidate, CBO-212, from the Company's Cloudbreak® platform, at the ESMO Targeted Anticancer Therapies Congress (ESMO TAT) in Paris, March 6-8, 2023. "The preclinical data presented at ESMO TAT represent important progress for Cidara in oncology, as…

SAN DIEGO, March 07, 2023 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, today announced the closing of its previously announced concurrent but separate underwritten public offerings of 11,086,000 shares of its common stock, including the exercise in full by the underwriter of its option to purchase an additional 1,446,000 shares of common stock, and 286,000 shares of…

SAN DIEGO, March 03, 2023 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, today announced the pricing of concurrent but separate underwritten public offerings of 9,640,000 shares of its common stock and 286,000 shares of its Series X Convertible Preferred Stock (each share of which is initially convertible into 10 shares of common stock), for aggregate expected gross…

SAN DIEGO, March 02, 2023 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, today announced concurrent but separate underwritten public offerings of its common stock and its Series X Convertible Preferred Stock. The closing of each proposed offering is not contingent upon the closing of the other. All shares to be sold in the offerings will be sold…

A single dose of CD388 decreased influenza viral replication in the upper respiratory tract and lowered influenza incidence rate in a human challenge model when compared to placeboCD388 was generally safe and well tolerated with no adverse events related to study drug reported as of the February 13, 2023 data cut-offOngoing study being conducted in collaboration with Janssen SAN DIEGO, March 01, 2023 -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics…